Compare Cronos Group Inc (CRON) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs FMC Corp — how do they compare? Cronos Group Inc trades at $3.19 (market cap $1.14B), while FMC Corp trades at $10.32 (market cap $1.30B). The key difference: Cronos Group Inc and FMC Corp are close in size by market cap, and FMC Corp pays a 3.07% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | FMC | |
|---|---|---|
Market Cap | $1.14B | $1.30B |
Sector | Health | Basic Materials |
52-Week High | $3.27 | $40.69 |
52-Week Low | $2.30 | $10.01 |
Enterprise Value | $341.13M | $5.11B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.165, up 5.5% with bullish technical signals from moving averages. The company shows strong revenue growth, with Q2 2026 beating expectations with $0.09 EPS versus $0.01 expected, and record quarterly performance. However, profitability remains inconsistent with negative net income in 2025. Analyst sentiment is mixed with 60% hold ratings, reflecting cautious optimism amid competitive pressures.
Outlook is cautiously optimistic with international expansion driving growth, but execution risks and cannabis sector volatility persist. The stock offers growth potential through European market penetration and product innovation, though investors should monitor margin improvements and competitive dynamics closely.
FMC Corporation (FMC) trades at $10.24, down 2.1% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows a bearish technical signal with key support at $10 and resistance at $11. Fundamentally, the company faces significant challenges with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though valuation ratios like P/S of 0.4 and P/B of 0.8 appear attractive. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide technology.
The outlook remains cautious due to persistent profitability issues and revenue declines, with 2025 revenue dropping to $3.47B from $4.2B in 2024. While analyst consensus is mixed with a $11.60 price target suggesting modest upside, high debt levels and competitive pressures pose substantial risks. The company's focus on debt reduction through asset sales and external investments provides some stability, but turnaround execution is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
